Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: Data from the French AIR registry

Journal of Rheumatology

Volumn 39, Issue 5, 2012, Pages 893-898

  Thomas, Laure ^a   Canoui Poitrine, Florence ^b,c   Gottenberg, Jacques Eric ^d   Economu Dubosc, Andra ^a   Medkour, Fatiha ^a   Chevalier, Xavier ^a   Bastuji Garin, Sylvie ^b,c   Le Louët, Hervé ^a   Farrenq, Valérie ^a   Claudepierre, Pascal ^a,b,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Psoriasis; Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB;

ADULT; AGED; DISEASE REGISTRY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRANCE; HUMAN; INCIDENCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; URINARY TRACT INFECTION;

ACUTE DISEASE; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; REGISTRIES;

EID: 84860783151     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111347     Document Type: Review

References (25)

1. European Medicines Agency. Summary product characteristics of Mabthera. [Internet. Accessed February 10, 2012.] Available from: http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/hu man/medicines/000165/human-med-000897. jsp&mid=WC0b01ac0 58001d124
2. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy; a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-8. (Pubitemid 41117439)
3. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, et al. New-onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumor necrosis factor a antagonists. Ann Rheum Dis 2006;65:405-7. (Pubitemid 43268235)
4. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview. Dermatology 2006;213:182-6. (Pubitemid 44567826)
5. Daens S, Scheers C, Semaille P, Bentin J. Flambée de psoriasis cutané sous adalimumab puis sous étanercept chez une patiente souffrant de polyarthrite rhumatoïde et d'une maladie de Crohn [Outbreak of psoriasis with adalimumab and then etanercept on a patient suffering from rheumatoid arthritis and Crohn's disease]. Rev Rhum 2006;73:1161.
6. Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor-a antagonist therapy: A case series. J Rheumatol 2007;34:380-5.
7. Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A. Flare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockers. Clin Exp Dermatol 2007;32:176-9. (Pubitemid 46233024)
8. Ritchlin C, Tausk F. A medical conundrum: Onset of psoriasis in patients receiving anti-tumor necrosis factor agents. Ann Rheum Dis 2006;65:1541-4. (Pubitemid 44799662)
9. Philipp S, Wolk K, Kreutzer S, Wallace E, Ludwig N, Roewert J, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets 2006;10:817-31. (Pubitemid 44816746)
10. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse skin reaction to anti-TNF alpha monoclonal therapy. Dermatology 2003;206:388-90. (Pubitemid 36677038)
11. Voulgari P V, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:567-70. (Pubitemid 351498443)
12. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15.
13. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8.
14. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
15. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
16. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9. (Pubitemid 39062719)
17. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
18. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, et al; MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR). Rheumatology 2010;49:1683-93.
19. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: Results from the SUNRISE trial. J Rheumatol 2010;37:917-27.
20. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-8. (Pubitemid 47237290)
21. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67:1056-7. (Pubitemid 351956683)
22. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 2009;27:996-8.
23. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
24. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: A population-based study. J Am Acad Dermatol 2009;60:394-401.
25. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-65. (Pubitemid 350277774)